Literature DB >> 30407161

Association of Acromegaly and Central Sleep Apnea Syndrome.

Ahmet Cemal Pazarlı1, Handan İnönü Köseoğlu1, Faruk Kutlutürk2, Erkan Gökçe3.   

Abstract

Acromegaly is usually characterized by the excessive secretion of growth hormone (GH) after the closure of epiphyseal plaques, resulting from functional pituitary adenomas. The most common manifestations of acromegaly are acral and soft tissue overgrowth, diabetes mellitus, hypertension, and heart and respiratory failure. In patients, obstruction of the upper airway may develop due to enlargement of the tongue and thickening of the tissues of the larynx; consequently, obstructive sleep apnea syndrome (OSAS) occurs commonly in acromegaly. Previous studies have shown an association between acromegaly and central sleep apnea syndrome (CSAS). Some of these described patients described showed that an elevation in the GH level may cause a defect in the respiratory drive. Most systemic diseases seen in acromegaly require effective treatment. We believe that it is necessary to perform effective treatments by examining respiratory disorders in sleep.

Entities:  

Year:  2017        PMID: 30407161      PMCID: PMC6453632          DOI: 10.5152/TurkThoracJ.2017.17003

Source DB:  PubMed          Journal:  Turk Thorac J        ISSN: 2148-7197


  8 in total

1.  Assessment of sleep apnea syndrome in treated acromegalic patients and correlation of its severity with clinical and laboratory parameters.

Authors:  L Vannucci; P Luciani; E Gagliardi; S Paiano; R Duranti; G Forti; A Peri
Journal:  J Endocrinol Invest       Date:  2012-07-09       Impact factor: 4.256

2.  Impact of successful treatment of acromegaly on overnight heart rate variability and sleep apnea.

Authors:  Denis Chemla; Pierre Attal; Luigi Maione; Anne-Sophie Veyer; Ghassan Mroue; Dany Baud; Sylvie Salenave; Peter Kamenicky; Serge Bobin; Philippe Chanson
Journal:  J Clin Endocrinol Metab       Date:  2014-04-29       Impact factor: 5.958

3.  Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study.

Authors:  Jose M Marin; Santiago J Carrizo; Eugenio Vicente; Alvar G N Agusti
Journal:  Lancet       Date:  2005 Mar 19-25       Impact factor: 79.321

Review 4.  Insulin resistance, glucose intolerance and diabetes mellitus in obstructive sleep apnoea.

Authors:  Brian D Kent; Walter T McNicholas; Silke Ryan
Journal:  J Thorac Dis       Date:  2015-08       Impact factor: 2.895

Review 5.  Systemic complications of acromegaly: epidemiology, pathogenesis, and management.

Authors:  Annamaria Colao; Diego Ferone; Paolo Marzullo; Gaetano Lombardi
Journal:  Endocr Rev       Date:  2004-02       Impact factor: 19.871

6.  Central sleep apnea is associated with increased ventilatory response to carbon dioxide and hypersecretion of growth hormone in patients with acromegaly.

Authors:  R R Grunstein; K Y Ho; M Berthon-Jones; D Stewart; C E Sullivan
Journal:  Am J Respir Crit Care Med       Date:  1994-08       Impact factor: 21.405

7.  Sleep apnea in patients with acromegaly. Frequency, characterization and positive pressure titration.

Authors:  Daniel Hernández-Gordillo; María Del Rocío Ortega-Gómez; Lourdes Galicia-Polo; Armando Castorena-Maldonado; Alma Vergara-López; Miguel Ángel Guillén-González; Luis Torre-Bouscoulet
Journal:  Open Respir Med J       Date:  2012-06-08

Review 8.  Acromegaly.

Authors:  Philippe Chanson; Sylvie Salenave
Journal:  Orphanet J Rare Dis       Date:  2008-06-25       Impact factor: 4.123

  8 in total
  2 in total

1.  Distribution Characteristics and Influencing Factors of Central Apnea in Chinese Pediatric Patients With Obstructive Sleep Apnea: A Single-Center Study.

Authors:  Jing Liu; Li Chang; Ling Cao; Guimin Huang
Journal:  Front Pediatr       Date:  2022-07-12       Impact factor: 3.569

2.  Evaluation of Acromegaly patients with sleep disturbance related symptoms.

Authors:  Deniz Celik; Sezgi Sahin Duyar; Funda Aksu; Selma Firat; Bulent Ciftci
Journal:  Pak J Med Sci       Date:  2021 Jul-Aug       Impact factor: 2.340

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.